Ana L. Rodríguez-Perea

Ana L. Rodríguez-Perea

Auto-generated profile, based on publicly available information

Ana L. Rodríguez-Perea

Grupo Inmunovirología, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2026 in Biomédica
Verified
Journal Article
Open access
PDF file
MCMaria Isabel Zapata Cardona
Maria Isabel Zapata Cardona
LELaura Milena Monsalve Escudero
Laura Milena Monsalve Escudero
ARAna L. Rodríguez-Perea
Ana L. Rodríguez-Perea
JCJuan D. Cerón
Juan D. Cerón
SESantiago Estrada
Santiago Estrada
WAWbeimar Aguilar-Jiménez
Wbeimar Aguilar-Jiménez
Introduction. Monkeypox cases have persisted in Colombia since the 2022 outbreak.Objective. To report the isolation and characterization of a monkeypox virus (MPXV) strain obtained from a Colombian patient during the 2022 outbreak, and to evaluate the antiviral potential of repurposed drugs against this isolate.Materials and methods. Lesion samples were inoculated into Vero-E6 cells. Viral isolation was characterized using virologic and molecular techniques. In addition, indirect immunofluorescence and neutralization assays were performed using convalescent serum. The antiviral activity of heparin, chloroquine, and ciprofloxacin was evaluated using a combined treatment strategy (multiplicity of infection = 2). Results. Cytopathic effect was observed 48 h post-infection. Viral titers reached 1.50 × 10⁶ PFU/ml. Phylogenetic analysis placed the isolate within clade IIb (B.1 lineage). Convalescent serum remained IFI-positive up to 1:160, and a 50% plaque reduction neutralization test of 35.6 was obtained. Chloroquine (50% inhibitory concentration ≈ 51.1 μM; selectivity index ≈ 2.2), heparin (50% inhibitory concentration ≈ 45.6 μg/ml; selectivity index ≈ 2.4), ciprofloxacin (50% inhibitory concentration ≈ 48.9 μM; selectivity index ≈ 3.9), and rifampicin (positive control; 50% inhibitory concentration ≈ 14.3 μM; selectivity index ≈ 19.7) significantly reduced MPXV infection. Molecular docking showed favorable binding of ciprofloxacin (-7.0 kcal/mol) and rifampicin (-7.2 kcal/mol) to the viral polymerase.Discussion. We successfully isolated and characterized an MPXV strain from a Colombian patient, establishing a platform for humoral and antiviral testing. Chloroquine, heparin, and ciprofloxacin showed measurable in vitro activity, supporting their potential for repurposing against this disease.